Glaxo Eyes Court Ruling On Seritide Patent

Law360, New York (March 11, 2004, 12:00 AM EST) -- A U.K. court is expected to decide later this month on the validity of a key patent on GlaxoSmithKline’s asthma drug Seritide.

Indian generic drugmaker Cipla has challenged a key U.K. patent on the drug, which expires in 2013, on the grounds of obviousness.

Cipla, along with Neolab — its distributor in the U.K. —filed a case in a London court in the first quarter of 2003, seeking revocation of one of the patents on Seretide, a combination of asthma drugs fluticasone and salmeterol.

GlaxoSmithKline also...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.